Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study

Jean-Jacques Kiladjian, Uma Borate, Elisabetta Abruzzese, Valerio De Stefano, Tiejun Gong, Massimo Breccia, Francesca Palandri, Fabrizio Pane, Andrea Patriarca, Hakon Reikvam, Lindsay Rein, Abdulraheem Yacoub, Feng Zhou, Michael Stouffs, Albert Assad, Alessandro Maria Vannucchi

Open source

DOI: 10.1093/oncolo/oyag201
Published: 2026-05-21
Container: The Oncologist
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyag201,
  title = {Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study},
  author = {Jean-Jacques Kiladjian and Uma Borate and Elisabetta Abruzzese and Valerio De Stefano and Tiejun Gong and Massimo Breccia and Francesca Palandri and Fabrizio Pane and Andrea Patriarca and Hakon Reikvam and Lindsay Rein and Abdulraheem Yacoub and Feng Zhou and Michael Stouffs and Albert Assad and Alessandro Maria Vannucchi},
  year = {2026},
  journal = {The Oncologist},
  doi = {10.1093/oncolo/oyag201},
  url = {https://doi.org/10.1093/oncolo/oyag201}
}

RIS

TY  - JOUR
TI  - Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study
AU  - Jean-Jacques Kiladjian
AU  - Uma Borate
AU  - Elisabetta Abruzzese
AU  - Valerio De Stefano
AU  - Tiejun Gong
AU  - Massimo Breccia
AU  - Francesca Palandri
AU  - Fabrizio Pane
AU  - Andrea Patriarca
AU  - Hakon Reikvam
AU  - Lindsay Rein
AU  - Abdulraheem Yacoub
AU  - Feng Zhou
AU  - Michael Stouffs
AU  - Albert Assad
AU  - Alessandro Maria Vannucchi
PY  - 2026
JO  - The Oncologist
DO  - 10.1093/oncolo/oyag201
UR  - https://doi.org/10.1093/oncolo/oyag201
ER  -

APA

Kiladjian, J., Borate, U., Abruzzese, E., Stefano, V. D., Gong, T., Breccia, M., Palandri, F., Pane, F., Patriarca, A., Reikvam, H., Rein, L., Yacoub, A., Zhou, F., Stouffs, M., Assad, A., & Vannucchi, A. M. (2026). Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study. The Oncologist. https://doi.org/10.1093/oncolo/oyag201

Source records

crossref · retrieved 2026-09-26T11:41:23.328Z